Alpha Europe Federation

ERS PRESIDENTIAL AWARD

This year the European Respiratory Society Presidential Award goes to Professor Robert Stockley.

Professor Stockley is a well-known figure in Alpha-1 circles.  

This well-deserved honour will be conferred at the ERS Congress in Munich on the 6th September, 2014.

The citation in the ERS Programme reads:

“Professor Robert A. Stockley is currently Professor of Medicine at the University Hospital Birmingham and director of the Lung Immunobiochemical Research Group. He has a longstanding interest in COPD phenotypes with particular reference to airway inflammation, proteinases and anti-proteinases. He is especially interested in the role of neutrophils and bacteria in exacerbations, and lectures widely on these subjects. He acts as advisor to many pharmaceutical companies on the design and delivery of Phase 2 and 3 clinical trials, and has been PI for several large multinational COPD trials. Professor Stockley organises the UK alpha-1-antitrypsin deficiency database and established the International Registry for the deficiency. He has been co-ordinating multicentre trials of augmentation therapy and alveolar regeneration in these patients. Since 1981, he has run a specialist clinic for patients with bronchiectasis with a particular interest in bacterial colonisation and its relationship to inflammation and immunity. He has published more than 400 peer-reviewed papers, reviews and chapters, edited seven books, supervised 35 higher degree theses in clinical and basic science, and been a member of the editorial board of more than 15 journals. He has been a member of the Executive Committee and is currently a member of the Scientific Committee of GOLD. He initiated and established the International meeting on COPD that is held every 2 years in Birmingham. He is currently finalising the programme for COPD 9 in 2014.”

Marketing Authorisation Application for Zemaira

 

The news that CSL Behring has submitted an application to the European Medicines Agency for Marketing Authorisation for their Zemaira Augmentation (Replacement) Therapy product is very significant.  Zemaira is already approved in the United States and if the application is successful the product will be available in the Members States of the European Union.